1. Home
  2. ALAB vs INSM Comparison

ALAB vs INSM Comparison

Compare ALAB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALAB
  • INSM
  • Stock Information
  • Founded
  • ALAB 2017
  • INSM 1988
  • Country
  • ALAB United States
  • INSM United States
  • Employees
  • ALAB N/A
  • INSM N/A
  • Industry
  • ALAB
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALAB
  • INSM Health Care
  • Exchange
  • ALAB NYSE
  • INSM Nasdaq
  • Market Cap
  • ALAB 7.3B
  • INSM 12.5B
  • IPO Year
  • ALAB 2024
  • INSM 2000
  • Fundamental
  • Price
  • ALAB $65.99
  • INSM $74.27
  • Analyst Decision
  • ALAB Strong Buy
  • INSM Strong Buy
  • Analyst Count
  • ALAB 11
  • INSM 16
  • Target Price
  • ALAB $73.09
  • INSM $83.29
  • AVG Volume (30 Days)
  • ALAB 4.1M
  • INSM 1.5M
  • Earning Date
  • ALAB 11-04-2024
  • INSM 10-31-2024
  • Dividend Yield
  • ALAB N/A
  • INSM N/A
  • EPS Growth
  • ALAB N/A
  • INSM N/A
  • EPS
  • ALAB N/A
  • INSM N/A
  • Revenue
  • ALAB $229,550,000.00
  • INSM $328,605,000.00
  • Revenue This Year
  • ALAB $203.18
  • INSM $19.10
  • Revenue Next Year
  • ALAB $48.86
  • INSM $44.67
  • P/E Ratio
  • ALAB N/A
  • INSM N/A
  • Revenue Growth
  • ALAB 44.97
  • INSM 21.94
  • 52 Week Low
  • ALAB $36.22
  • INSM $21.92
  • 52 Week High
  • ALAB $95.21
  • INSM $80.53
  • Technical
  • Relative Strength Index (RSI)
  • ALAB N/A
  • INSM 52.83
  • Support Level
  • ALAB N/A
  • INSM $69.08
  • Resistance Level
  • ALAB N/A
  • INSM $77.70
  • Average True Range (ATR)
  • ALAB 0.00
  • INSM 2.25
  • MACD
  • ALAB 0.00
  • INSM 0.44
  • Stochastic Oscillator
  • ALAB 0.00
  • INSM 60.21

About ALAB ASTERA LABS INC

Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Share on Social Networks: